Visior Technologies

Company Overview

Snapshot

Founded in January 2013 by Ilan Vadai, Yuval Avni, and Hans Brocker, Visior Technologies operates with 1–10 employees. The company is currently in a Pre-Funding stage and ceased operations in September 2023.

Business overview

Visior Technologies is a clinical-stage medical device company focused on Health Tech & Life Sciences, specifically within Digital Healthcare and Digital Therapeutics. The company developed a commercial video-based, non-invasive platform that delivers visual and auditory stimulation to induce changes in cerebral blood flow, brain perfusion, retinal blood flow, and neural connectivity in the visual system. This technology, including its product ReviView, is designed to complement existing medication treatments and enable new treatment modalities for neurodegenerative conditions such as Parkinson's and Alzheimer's disease, as well as eye-related conditions like amblyopia and glaucoma. The company operates on B2B2C and B2B business models, targeting patients within the healthcare sector.

Strategic signal

In January 2019, research published in bjo.bmj.com highlighted the effects of Visior Technologies' image brightness and contrast dynamic altering stimuli (DAS) on ocular blood flow when viewing video content. This publication indicates the company's commitment to validating its technology through scientific research, providing a signal of its potential for evidence-based applications in ophthalmology and related fields.

Company Intelligence Q&A

What is Visior Technologies' primary focus?

Visior Technologies focuses on developing a clinical-stage medical device platform for eye and brain stimulation treatment, primarily within the Health Tech & Life Sciences sector.

When was Visior Technologies founded and by whom?

Visior Technologies was founded in January 2013 by Ilan Vadai, Yuval Avni, and Hans Brocker.

What is the core technology behind Visior Technologies' platform?

The company's core technology involves a video-based, non-invasive delivery system that uses visual and auditory stimulation to influence cerebral and retinal blood flow, perfusion, and neural connectivity.

What conditions does Visior Technologies' treatment aim to address?

Visior Technologies' stimulation treatment is intended to complement medication and enable new treatment modalities for neurodegenerative conditions like Parkinson's and Alzheimer's, as well as eye conditions such as amblyopia and glaucoma.

What was a key research finding related to Visior Technologies' technology?

In January 2019, research published in bjo.bmj.com detailed the effects of Visior Technologies' dynamic altering stimuli (DAS) on ocular blood flow when viewing video content.